IMPACT Therapeutics has received the China National Medical Products Administration (NMPA) marketing authorisation for ...

High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced ...

In recent years, PARP inhibitors are changing the therapeutic landscape of ovarian cancer, with maintenance therapy extending the duration of sustained remission after platinum-containing chemotherapy ...

A nurse, foster mom and the primary provider for a family of eight, Shelly Sepulveda has devoted her life to taking care of ...

Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer.

The theory is solid, but creating such a bespoke vaccine quickly enough to be of use is a different matter. “Not many years ...

While the announcement is good news for the Princess of Wales, cancer experts describe the challenges of a life shadowed by ...

Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, ...

ovarian cancer progressing under taxane/carboplatin chemotherapy or in early relapse (< 6 months).

Shares of Verastem Oncology (VSTM) are up over 40% at $5.17 in premarket trading Tuesday, following a regulatory update. The ...

However, GSK said that the trial evaluating Zejula and Jemperli in first line advanced ovarian cancer failed to meet statistical significance in improving overall survival as a key secondary endpoint.